A Pfizer vaccine is being, rolled out in Pakistan. The company is in talks with the Pakistani government to provide the mRNA vaccine through its global shared vaccine programme COVAX, which aims to provide equitable access to approved vaccines. The vaccine intend to protect health workers, social workers, and other high-risk groups. The rollout expects to begin late in May 2021, with over 100,000 doses shipped from the United States. The vaccine will ultimately given to 17 million individuals through the COVAX facility.
COVAX
In February, the Pakistani government dispatched 13,000 teams of health workers to Sindh province to administer COVAX Pfizer vaccines to the area’s residents. The goal is to reach 25% of the population who are yet to receive their first dose of the vaccine. The government’s vaccination program relies on donated Chinese vaccines to help meet the shortage of Western-developed anti-coronavirus shots.
This latest development represents an important milestone in the fight against the pandemic, and it is also a strong symbol of international solidarity. As the second-largest donor to the COVAX vaccine program, Germany commits to provide equitable access to vaccines around the world. After all, no one is truly safe until everyone is, protected.
As part of its global vaccine diplomacy, the United States is sending more than a million doses of the COVAX Pfizer vaccine to Pakistan. Since June, shipments of this vaccine have been sent to Pakistan on a monthly basis. This initiative will make sure that all of the country’s citizens have access to the vaccines they need.
Since July, the United States has shipped more than half a million doses of COVID-19 vaccine to Pakistan, bringing the total to 18.3 million doses. In addition to the Pfizer COVID-19 vaccine, the U.S. government has also shipped a few other manufacturers’ vaccines to Pakistan. With these shipments, the government of Pakistan will be able to reach its goal of vaccinating at least 20% of its population.
The government of Pakistan’s efforts in the area of COVID-19 protection has commended by Gavi. The global organization is aiming to provide two billion doses of COVID-19 vaccines to all participating countries by 2021. The vaccines aim at protecting frontline health workers and vulnerable groups.
Several vaccine companies are working together to deliver COVAX vaccines to underserved communities in the developing world. The World Health Organization, Gavi, and the World Bank are supporting this global initiative. These organizations provide funding for this vaccine, which has helped millions of children worldwide.
Oxford-AstraZeneca
A new vaccine for the deadly COVID virus has approved for use in Pakistan by the government’s drug regulatory agency. The British-Swedish multinational pharmaceutical company AstraZeneca designed and manufactured the COVID-19 vaccine. In the first phase, the vaccine will be given to health workers and older people. It is currently being tested in clinical trials by the Chinese firm CanSino in Pakistan, with registration expected next month.
AstraZeneca and the University of Oxford collaborated on the vaccine, which uses ChAdOx1 technology. This technology was previously developed to treat influenza and the middle east respiratory syndrome. The Oxford-AstraZeneca vaccine has successfully tested in the UK, Brazil, and other countries. AstraZeneca is also testing the vaccine in the country, involving 40,000 people.
The vaccine has a mild to moderate side effect profile. Symptoms may include thrombocytopenia and thrombotic reactions. If these symptoms occur, the patient should seek immediate medical care. Other adverse effects include a persistent or severe headache, backache, or chest pain.
Both Oxford-AstraZeneca and Pfizer-BioNTech vaccines are based on genetic technologies. They are, made in a laboratory by producing adenovirus, a virus that carries genetic material from outside to cells inside the body. The adenovirus is grown in chicken or HEK-293 cells.
Vaccines should use in accordance with official recommendations. In Pakistan, the Oxford-AstraZeneca vaccine for the COVID virus is being trialled for use in low and middle-income countries. However, the vaccine may not be available in all countries.
Pfizer
The federal government has signed an agreement with pharmaceutical giant Pfizer to supply its vaccine to Pakistan. The vaccine has restricted to those with low immunity and to travellers. A batch of the Pfizer vaccine should arrive in Pakistan by July, and another batch is, expected by the end of this year. The prime minister’s aide confirmed that the government has received a limited supply of Pfizer this month, and promised that it would increase its supply by the end of this year.
Since the beginning of last year, the United States has shipped more than 30 million doses of COVID-19 vaccine to Pakistan. This includes three million doses donated by Pfizer. In addition, the US Embassy in Islamabad, charged with the vaccination program. The Pfizer vaccine is one of several vaccines, given to the Pakistani public.
Pfizer vaccine is, given to people who are high-risk for COVID and chronic hepatitis. It must store in cold temperatures ranging from minus 60 to 80 degrees Celsius and kept away from light. The first dose of the Pfizer vaccine should be given to healthy adults; it is not given to pregnant women and breastfeeding women. Those with severe allergies or a history of COVID-19 should avoid the Pfizer vaccine.
The Pfizer vaccine is the most recent addition to the list of approved vaccines in Pakistan. It was, granted approval by the Drug Regulatory Authority of Pakistan, and is now available to the public. However, there are several concerns about this vaccine. As with any vaccine, there are a variety of side effects that associate with it.
The vaccination drive has started in Pakistan and is, targeted at children aged twelve and older. The vaccination campaign also aims at adults who are over the age of twelve. The government should continue its efforts in combating these rumors and help more families get, vaccinated. It’s crucial for the government of Pakistan to continue working on the issue.
The United States is sending 3 million doses of the Pfizer vaccine to Pakistan and Bangladesh, following a $500 million purchase of vaccine from Pfizer in the summer of 2021. This is a landmark for the global vaccine campaign. It also represents a strong symbol of international solidarity. Germany is the second largest donor of the vaccine, contributing 1.5 billion EUR for the vaccine facility. Germany is, convinced that the world needs global access to vaccines – no one is safe until everyone is safe.
Sinovac
The Sinovac Pfizer vaccine is, safe and effective for all age groups, recommended for older adults. It can be given as an extension of the primary series for people who need additional protection. However, this vaccine is not, recommended for children younger than 12 years old, or individuals with severe or moderate immunosuppression. These groups are at increased risk of developing severe COVID-19 disease.
The vaccine is effective in Pakistan, but it has a lower efficacy rate than other vaccines. In a study conducted in Sri Lanka, the vaccine was only 50 percent effective against the Delta variant of the SARS-CoV-2 virus, which is an emerging strain. However, it is still the only vaccine that is 100 percent effective against this strain. Despite its lower efficacy level, the vaccine is still, considered a good choice for Pakistani children.
CanSino has already recruited more than 20,000 participants for its phase three trials. Its vaccines currently test in Pakistan, the United States, Mexico, and Chile. It is a peptide vaccine that uses a subunit of the pathogen to trigger an immune response. The vaccine has already approved in China, Indonesia, and Uzbekistan. It was recently, published in the Lancet and has received FDA approval.
While the phase 3 and 4 trials have not yet concluded, it expects that the Sinovac Pfizer vaccine will be safe and effective for pregnant women. There is no need to delay or stop pregnancy due to the vaccine. This vaccine is a safe and effective way to prevent the COVID-19 virus.
Several cases of CNS demyelination have reported. The CNS demyelination was the first symptom of CNS demyelination. Moreover, a painful sensation behind the right eye and pain on eye movement were reported. The patient was diagnosed with CNS demyelination after the first dose of the vaccine. MRI revealed three new T2 hyperintense white matter lesions in her brain.
